pharma news today obesity drugs glp-1 A $60 billion industry just found its next growth lever. π With the expiry of a key patent on March 20, 2026, Indian majors are launching generic weight-loss and diabetes GLP-1 Agonists Market Report 2025-2033,
Description
Foundayo was FDA-approved in April 2026 and is available at Endocare in Dubai and Abu Dhabi
Their formulations are rooted in cutting-edge microbiome science and designed to support metabolism, gut barrier health, and even cravings while helping to maintain healthy blood sugar* by delivering next-generation, live probiotic strains to the gut
This approach helps regulate appetite and maintain stable blood sugar levels
68 RoumesH.DumontU.SanchezS.MazuelL.BlancJ.RaffardG.et al (2021)
Certain groups of people should not use Semaglutide GLP-1 or should use it with caution under healthcare professional supervision
